Disease · HP_0031292
Cutaneous abscess
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Cutaneous abscess. Diseases, record HP_0031292. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0031292
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Cutaneous abscess
- Open Targets ID
- HP_0031292
- Other names
- Skin abscess
- Highest stage of its drugs
- Phase 3, for 2 of its 6 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TRIMETHOPRIM | CHEMBL22 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| CO-TRIMOXAZOLE | CHEMBL58061 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 0 | Drugs and targets |
| CEPHALEXIN | CHEMBL1200544 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CLINDAMYCIN | CHEMBL1753 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SULFAMETHOXAZOLE | CHEMBL443 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TOBRAMYCIN | CHEMBL1747 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets0
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
None in this release.
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00729937 | Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA" | Phase 2/3 | 2,265 | 2014-05-28 | Staphylococcal Infection | CEPHALEXIN, CLINDAMYCIN, SULFAMETHOXAZOLE, TRIMETHOPRIM | Its record names the disease | ClinicalTrials.gov |
| NCT02024867 | Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage | Not applicable | 249 | 2014-09-15 | Skin Disease, Bacterial, Abscess | TRIMETHOPRIM | Its record names the disease | ClinicalTrials.gov |
| NCT00973765 | Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses | Phase 3 | 212 | 2010-03-02 | Abscesses | TRIMETHOPRIM | Its record names the disease | ClinicalTrials.gov |
| NCT00867789 | Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department | Not applicable | 140 | 2021-01-26 | Abscess | TRIMETHOPRIM | Its record names the disease | ClinicalTrials.gov |
| NCT00822692 | Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection | Not applicable | 139 | 2009-09-03 | Abscess, Methicillin-Resistant Staphylococcus Aureus Infection | TRIMETHOPRIM | Its record names the disease | ClinicalTrials.gov |
| NCT00829686 | Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection | Not applicable | 31 | 2009-07-28 | Abscess | TRIMETHOPRIM | Its record names the disease | ClinicalTrials.gov |
| NCT02334384 | Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess | Phase 1/2 | 6 | 2018-08-29 | Furunculosis | TOBRAMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT00900510 | Antibiotic Therapy After Incision and Drainage for Abscess | Not applicable | 0 | Abscess | TRIMETHOPRIM | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Active Comparator vs Placebo: serious adverse events | 0 of 212 | 0 of 212 | 424 | NCT00973765 | Trial comparisons |
| 3 Days vs 10 Days: Treatment Failures | 9 of 125 | 4 of 124 | 249 | NCT02024867 | Trial comparisons |
| 3 Days vs 10 Days: serious adverse events | 0 of 125 | 0 of 124 | 249 | NCT02024867 | Trial comparisons |
| 3 Days vs 10 Days: Recurrent Skin Infections | 21 of 115 | 9 of 118 | 233 | NCT02024867 | Trial comparisons |
| Active Comparator vs Placebo: Treatment Failures at 7 Days | 15 of 96 | 27 of 116 | 212 | NCT00973765 | Trial comparisons |
| Trimethoprim-sulfamethaxazole vs Sugar Pill: serious adverse events | 0 of 70 | 0 of 70 | 140 | NCT00867789 | Trial comparisons |
| Bactrim DS (800/160) Two Tablets PO BID x 7 Days vs Matched Placebo 2 Pills PO BID x 7 Days: serious adverse events | 0 of 63 | 0 of 76 | 139 | NCT00822692 | Trial comparisons |
| 3 Days vs 10 Days: Treatment Failures Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | 8 of 69 | 1 of 69 | 138 | NCT02024867 | Trial comparisons |
| 3 Days vs 10 Days: Recurrent Skin Infections Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | 8 of 60 | 2 of 67 | 127 | NCT02024867 | Trial comparisons |
| Bactrim DS (800/160) Two Tablets PO BID x 7 Days vs Matched Placebo 2 Pills PO BID x 7 Days: Recurrence Rates of Abscesses | 4 of 46 | 14 of 51 | 97 | NCT00822692 | Trial comparisons |
1 to 10 of 17
See all 17 comparisons in its trialsPapers from its trials7
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0031292
GET https://conductscience.org/api/diseases/v1/HP_0031292/drugs